Pine Labs IPO Opens for Subscription: Check GMP, Price Band, Dates & Review

The Pine Labs IPO opened for investors on Friday, November 7, 2025, and the company aims to collect about ₹3,899.9 crore through this issue. The issue consists of a fresh share sale worth ₹2,080 crore and an offer for sale (OFS) of ₹1,819.91 crore.

The company has fixed the price band between ₹210 and ₹221 per share, with a lot size of 67 shares per application. Before the IPO launch, Pine Labs raised ₹1,753 crore from 70 institutional investors in an anchor round at ₹221 per share. Major investors such as SBI Mutual Fund, Nomura, HSBC, ICICI Prudential Life, Tata Mutual Fund, and Morgan Stanley participated in the anchor book.

The IPO subscription window will remain open from November 7 to November 11, 2025, and the share allotment is expected on November 12, 2025. The company’s shares are likely to be listed on the NSE and BSE on November 14, 2025.

In the grey market, Pine Labs shares are trading at ₹233, which is ₹12 or 5.5% higher than the upper price band of ₹221, indicating moderate investor interest ahead of listing.

According to market analysts the response to the IPO is mixed. Angel One has given a Neutral rating, citing that the company remains loss-making and appears overvalued compared to its listed peers. Similarly, Arihant Capital has rated the IPO as Avoid, highlighting high employee, technology & acquisition costs as challenges impacting profitability.

The money raised from the IPO will be used to repay debts, improve IT and cloud systems, develop new technologies, and expand Pine Labs’ business in other countries, including Singapore, Malaysia, and the UAE. Kfin Technologies is the registrar of the issue, while Axis Capital, Morgan Stanley India, JP Morgan India & Jefferies India are the lead book-running managers.

Read Also: Realme GT 8 Pro India Launch on November 20: Snapdragon 8 Elite Gen 5, 7,000mAh Battery & More

Overall the Pine Labs IPO 2025 presents a strong growth story in the fintech space but comes with valuation concerns. Investors are advised to evaluate their risk appetite before subscribing.